Parra Sonia G, López-Orellana Leticia M, Molina Duque Adán R, Carns Jennifer L, Schwarz Richard A, Smith Chelsey A, Ortiz Silvestre Marya, Diaz Bazan Salvador, Escobar Pablo A, Felix Juan C, Ramalingam Preetha, Castle Philip E, Cremer Miriam L, Maza Mauricio, Schmeler Kathleen M, Richards-Kortum Rebecca R
Department of Bioengineering, Rice University, Houston, Texas, USA.
Basic Health International, San Salvador, El Salvador.
Int J Cancer. 2021 May 15;148(10):2571-2578. doi: 10.1002/ijc.33454. Epub 2021 Jan 9.
Cervical cancer remains a leading cause of cancer death for women in low- and middle-income countries. The goal of our study was to evaluate screening and triage strategies, including high-resolution microendoscopy (HRME), to detect cervical abnormalities concerning for precancer at the point of care. Women (n = 1824) were enrolled at the Instituto de Cáncer de El Salvador. All underwent screening by both human papillomavirus (HPV) testing using careHPV and visual inspection with acetic acid (VIA). Screen-positives, along with 10% of screen-negatives, were invited to return for a follow-up examination that included triage with VIA, colposcopy and HRME imaging. Biopsies were taken of any abnormalities identified. If no abnormalities were identified, then the worst scoring site by HRME was biopsied. The sensitivities of HPV testing and VIA to screen for cervical intraepithelial neoplasia Grade 2 or more severe diagnoses (CIN2+) were 82.1% and 75% (P = .77), while the specificities were 90.4% and 80.9% (P < .001), respectively. The sensitivities of VIA, colposcopy and HRME as triage tests for CIN2+ were 82.1%, 82.1% and 71.4%, respectively (P ≥ .38). HRME had a significantly higher specificity (66.7%) than VIA (51.9%) (P < .001) and colposcopy (53.3%) (P < .001). When evaluating different theoretical screening and triage strategies, screening with HPV testing followed by triage with HRME would result in more women receiving appropriate care (97%) compared to screening with VIA (75%) or HPV alone (90%). Our findings demonstrate that screening with HPV is superior to VIA, and that triage with HRME imaging increases the specificity of detecting CIN2+ at the point of care in a low-resource setting.
在低收入和中等收入国家,宫颈癌仍是女性癌症死亡的主要原因。我们研究的目的是评估包括高分辨率显微内镜检查(HRME)在内的筛查和分流策略,以便在医疗现场检测出可疑癌前病变的宫颈异常情况。1824名女性在萨尔瓦多癌症研究所登记入组。所有人都接受了使用careHPV进行的人乳头瘤病毒(HPV)检测以及醋酸肉眼观察法(VIA)筛查。筛查呈阳性者,以及10%的筛查阴性者,被邀请回来接受后续检查,包括VIA分流、阴道镜检查和HRME成像。对任何发现的异常进行活检。如果未发现异常,则对HRME评分最差的部位进行活检。HPV检测和VIA筛查宫颈上皮内瘤变2级或更严重诊断(CIN2+)的敏感度分别为82.1%和75%(P = 0.77),而特异度分别为90.4%和80.9%(P < 0.001)。VIA、阴道镜检查和HRME作为CIN2+分流检测的敏感度分别为82.1%、82.1%和71.4%(P≥0.38)。HRME的特异度(66.7%)显著高于VIA(51.9%)(P < 0.001)和阴道镜检查(53.3%)(P < 0.001)。在评估不同的理论筛查和分流策略时,与单独使用VIA(75%)或单独使用HPV(90%)进行筛查相比,先进行HPV检测再用HRME进行分流的筛查方式会使更多女性获得适当治疗(97%)。我们的研究结果表明,HPV筛查优于VIA,并且在资源匮乏地区的医疗现场,HRME成像分流可提高检测CIN2+的特异度。